Le Lézard
Classified in: Health, Science and technology, Business
Subject: FINANCING AGREEMENTS

Angiochem and Xinogen to Enter License Agreement



HONG KONG, CHINA and MONTREAL, QC--(Marketwired - January 03, 2018) - Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group Ltd. entered a license and collaboration agreement to develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer. Xinogen was granted exclusive rights to develop and commercialize ANG1005 in the Greater China region. In return, Angiochem will receive upfront and milestone payments as well as a royalty based on future product sales.

Angiochem is currently developing ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer. The company's next clinical trial is due to start in 2018. "Angiochem is looking forward to collaborating with Xinogen," said John Huss, Executive Chairman of Angiochem. Dr. Kun Meng, CEO of Beijing Shenogen Pharma Group Ltd., also expressed his enthusiasm and confidence about collaborating with Angiochem.

About Angiochem:

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.

About Beijing Shenogen Pharma Group Ltd.:

Beijing Shenogen Pharma Group is a drug discovery and development company founded in 2006 based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. The Company possesses robust intellectual property rights around novel targets for anticancer therapies. Additional information is available at http://www.shenogen.com.


These press releases may also interest you

13 déc 2018
The timeless Round Hill Hotel and Villas has been a beloved escape for travelers seeking a resort with rich history and modern luxury. This year, Round Hill is introducing new additions and updates on property, including the renovation of four...

13 déc 2018
Louise Jones-James is recognized by Continental Who's Who as a Pinnacle Lifetime Member in the field of Finance and Operations in recognition of her role as a Finance & Operations Leader/Founder and CEO of Finance & Operations Leadership Consulting....

13 déc 2018
Palomar Display Products, Inc. announced today that it has been awarded two contracts totaling $1.3M to deliver military display systems for the US Army armored vehicles. The orders include Next Generation Image Control Units (NGICU) digital color...

13 déc 2018
Dubai based international entrepreneur and philanthropist Ghassan Aboud was awarded for "Excellence in International Business" at the 2018 Enterprise Agility Awards ? Entrepreneur of the Year held at the Hilton Hotel, Habtoor City, Dubai on December...

13 déc 2018
Aristocrat was joined by a delegation of local, state, and international dignitaries to cut the ribbon at the company's new two-building campus in the Las Vegas neighborhood Summerlin. Participating in the ceremony were...

13 déc 2018
Economic growth across the Asia-Pacific region will continue in 2019, but is expected to slow amid a global economic downturn Bank of the West Chief Economist Scott Anderson said at the 24th Annual Pacific Rim Client Appreciation Dinner. Emphasizing...




News published on 3 january 2018 at 11:03 and distributed by: